Given the large amount of literature implicating endothelial dysfunction in disease contexts ranging from aging to atherosclerosis to hypertension, our data suggest that activators of SIRT6 could represent a novel class of therapeutic compounds with broad clinical utility. Here, SIRT6 is linked to Hypertension.